Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
Delivered directly into your bloodstream, it helps fight fatigue, reduce stress, and improve clarity, perfect for busy professionals, athletes, or anyone with low B12 levels
Research has explored the compounds role in adipocyte systems, including investigations into lipid accumulation patterns and related metabolic processes
If the deficiency is severe, remarkably, it can lead to permanent nerve damage
Once reconstituted for research it is kept at 2-8 degrees C and typically used within 28 days
Promotes Joint & Tendon Recovery Effective for healing sprains, strains, and chronic injuries